Skip to main content

Table 6 Summary of multivariate analysis in all patients with neoadjuvant chemotherapy showing the odds ratio (95% confidence interval) of variables significantly associated with PD-L1 scoring methods and sTIL level

From: Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

Factor

TC22C3

TCIC22C3

IC22C3

sTIL level

Race/ethnicity

 White+Latino vs. Black

0.10 (0.01, 0.76)a

   

 Others vs. Black

NS

   

Histologic grade

 3 vs. 1 + 2

 

7.27 (1.94, 27.24)b

4.94 (1.31,18.73)a

4.38 (1.84, 10.45)c

sTIL level

 ≥ 10% vs. < 10%

6.10 (1.18, 41.16)a

6.71 (2.37, 18.99)c

4.39 (1.49, 12.85)b

 

Receptor group

 ER/PR pos vs. TNBC

0.10 (0.01, 0.63)b

   

 HER2 vs. TNBC

NS

   

Tumor size

 > 2 to 5 cm vs. ≤2 cm

   

NS

 > 5 cm vs. ≤2 cm

   

0.26 (0.09, 0.76)a

  1. NS not significant
  2. aP value < 0.05–0.01
  3. bP value < 0.01–0.001
  4. cP value < 0.001